Parkinson's Disease | Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
Parkinson's Disease research study
What is the primary objective of this study?
The purpose of this research study is to measure the safety (side effects) of an Omega 3 Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary movements) in Parkinson 's disease (PD).
Who is eligible to participate?
Inclusion Criteria: - Diagnosed with Parkinsons disease - No levodopa (Sinemet) treatment or prior exposure to levodopa Exclusion Criteria: - Prior exposure to levodopa - Unable to stand for 1 minute without aid - Sensory deficits on feet - Significant cognitive impairment - Current use of dopamine receptor blocking medications (depakote, lithium, amiodarone, tetrabenazine, metoclopramide, dronabinol) - Current fish oil or lutein supplementation - Allergy to soy
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:Docosahexaenoic Acid (DHA)Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
Drug:PlaceboSugar Pill, taken for 1.5 years
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Arm 1Docosahexaenoic Acid (DHA)
Start Date: October 2012
Completed Date: June 2016
Phase: Phase 1
Primary Outcome: Efficacy of DHA - Change in Blood ng/dL Levels
Secondary Outcome: Forceplate Measured Dyskinesia
Study sponsors, principal investigator, and references
Principal Investigator: Kathryn Anne Chung, MD
Lead Sponsor: VA Office of Research and Development
Collaborator: Oregon Health and Science University
Salem N Jr, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids. 2001 Sep;36(9):945-59. Review.
Péchevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M; Trial Study Group. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005 Dec;12(12):956-63.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484-91.
Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol. 2002 Jun;51(6):686-93.
Chung KA, Lobb BM, Nutt JG, McNames J, Horak F. Objective measurement of dyskinesia in Parkinson's disease using a force plate. Mov Disord. 2010 Apr 15;25(5):602-8. doi: 10.1002/mds.22856.